Olema Oncology, Inc. (OLMA) company profile
Close on Nov 17, 2026Market cap $631.73MP/E –Yield –
About Olema Oncology
Pharmaceutical Preparations, SIC 2834
Olema is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing targeted therapies for breast cancer and other hormone-driven cancers. The company's lead investigational candidate is palazestrant, an oral small molecule acting as a complete estrogen receptor antagonist and selective estrogen receptor degrader. Olema is advancing palazestrant in late-stage clinical trials both as a single agent and alongside approved targeted medicines for patients with advanced or metastatic breast cancer. A second clinical-stage candidate, OP-3136, functions as a selective inhibitor of KAT6 for breast cancer and other solid tumors. Olema does not currently have approved products or commercial sales, serving patients through clinical trials.
The company operates without internal manufacturing facilities, relying entirely on third-party contract organizations for drug production and supply. Olema conducts clinical studies in collaboration with pharmaceutical partners such as Novartis and Pfizer across target populations primarily in the United States and Europe. The provided text does not state the company's specific headquarters location.
Summary of the business section of Olema Oncology's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Olema Oncology, Inc.
- Headquarters
- San Francisco, CA
- Address
- 780 Brannan Street 94103
- Phone
- (415) 651-3316
- Website
- olema.com
- Employees
- 131, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, New Jersey
Stock & identifiers
- Ticker
- OLMA
- Exchange
- Nasdaq
- IPO date
- Nov 19, 2020
- Shares outstanding
- 87M, Aug 6, 2026
- Public float
- $243.10M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1750284
- CUSIP
- 68062P106
- ISIN
- US68062P1066
- FIGI
- BBG00T5JMRT4
- Share class FIGI
- BBG00T5JMRV1
- EIN
- 30-0409740
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sean Bohen | PRESIDENT AND CEO, Director | 237,650 |
| Jason O'Byrne | CHIEF FINANCIAL OFFICER | – |
| Shawnte Mitchell | CHIEF LEGAL OFFICER | 233 |
| Sasha Lu Austin | VP of Finance and Controller | 4,488 |
| Naseem Zojwalla | CHIEF MEDICAL OFFICER | 103,997 |
| David C. Myles | CH. DISCOV. & NON-CLIN DEV OFF | 687,607 |
| Shane William Charles Kovacs | CH. OPERATING & FINANCIAL OFF. | 139,727 |
| Cyrus Harmon | Director | 819,798 |
| Prakash Raman | Director | – |
| Value Fund L. P. Biotechnology | Director | 2,906,659 |
| Partners OS Ltd. BVF | Director | 447,526 |
| Ii Gp Llc Bvf | Director | 623,707 |
| Value Trading Fund OS LP Biotechnology | Director | 3,684,068 |
| Ian T. Clark | Director | 0 |
| Cynthia M. Butitta | Director | 83,876 |
| Andrew Rappaport | Director | 385,965 |
| J. Scott Garland | Director | – |
| Mark N. Lampert | Director | 2,103,522 |
| I. Gp Llc Bvf | Director | – |
| Inc/Il Bvf | Director | 2,103,522 |
| Yi Larson | Director | – |
| Gp Holdings Llc Bvf | Director | – |
| Partners L. P/Il Bvf | Director | – |
| Value Fund Ii Lp Biotechnology | Director | 2,523,265 |
| Sandra Horning | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $3.18M | $25.16M | $1.97M | $1020 | – |
| FY2024 | $8.13M | -$4.60M | $3.63M | $238 | – |
| FY2023 | $3.15M | $22.26M | $1.39M | $573 | – |
| FY2022 | $5.99M | -$3.27M | $2.26M | $5 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Sean Bohen, M.D., Ph.D. President and Chief Executive Officer | $699.92K | – | $2.00M | $461.90K | $15.17K | $3.18M | -61% |
| Shane Kovacs Chief Operating and Financial Officer | $562.64K | – | $985.60K | $324.93K | $15.17K | $1.89M | -56% |
| Shawnte Mitchell, J.D. Chief Legal Officer and Corporate Secretary | $391.88K | $50.00K | $1.39M | $207.90K | $14.98K | $2.05M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Nov 19, 2020
- Offer price
- $19.00
- Securities offered
- 11,000,000
- Gross proceeds
- $209.00M
- Exchange
- Nasdaq
- First trading day
- Nov 19, 2020
- First-day close
- $49.00+157.9%
- Lock-up ends (est.)
- May 18, 2021
“The initial public offering price is $19.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of January 31, 2026, we had 131 employees, all of whom were full time, consisting of clinical, research, operations, regulatory, and administrative personnel.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 19, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 17, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?